A federal jury in Delaware ruled in favor of Regeneron Pharmaceuticals Inc., awarding them $406.8 million in their antitrust lawsuit against Amgen Inc.
Regeneron accused Amgen of employing anti-competitive practices by bundling its cholesterol drug, Repatha, with significant rebates on its anti-inflammatory drugs, Otezla and Enbrel. This strategy, Regeneron argued, incentivized pharmacy benefit managers (PBMs) to remove Regeneron's competing cholesterol drug, Praluent, from their formularies.
The jury sided with Regeneron, finding Amgen's actions to be in violation of antitrust laws. The substantial financial award reflects the jury's assessment of the harm caused by Amgen's practices.
Last week, federal jurors in Delaware awarded Regeneron Pharmaceuticals Inc. more than $400 million in its antitrust showdown with Amgen Inc., the company’s rival in the market for cholesterol drugs that block the protein PCSK9.
Regeneron accused Amgen of illegally bundling its cholesterol treatment Repatha with substantial rebates on a pair of blockbuster anti-inflammatory drugs—Otezla and Enbrel—to induce pharmacy benefit managers to drop Regeneron’s Praluent from their offerings.
If you often open multiple tabs and struggle to keep track of them, Tabs Reminder is the solution you need. Tabs Reminder lets you set reminders for tabs so you can close them and get notified about them later. Never lose track of important tabs again with Tabs Reminder!
Try our Chrome extension today!
Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more